Amgen to pay $150M for misbranding Aranesp
[Editor’s note: This story has been updated with comments from Amgen.] Biotech giant Amgen pleaded guilty Dec. 18 to a misdemeanor charge for misbranding its anemia drug Aranesp. According to a report from Bloomberg News, the Thousand Oaks-based firm agreed to pay $150 million in fines and penalties as part of the guilty plea. U.S. Read More →
Read More →Amgen buys DeCode Genetics for $415M
Biotech giant Amgen is buying Icelandic genetics research firm DeCode Genetics for $415 million, the Thousand Oaks company said Dec. 10. The all-cash deal is expected to close before the end of the year and will give Amgen, the largest biotechnology firm in the world, opportunities to develop new medicines that target defective DNA. “DeCode Read More →
Read More →Amgen Tour to hit Santa Barbara, Avila Beach
[Editor’s note: This story has been updated with additional information.] The Amgen Tour of California will return to Santa Barbara and visit Avila Beach for the first time ever when the Tri-Counties hosts the end of Stage 4 and all of Stage 5 for the eight-year-old road cycle racing event next year. AEG, presenter of Read More →
Read More →
Amgen aims to put cholesterol drug on market
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen case before SCOTUS could stymie new class-action suits
On Nov. 5, Thousand Oaks-based Amgen argued a case before the U.S. Supreme Court that could make it much harder for shareholders to form a class when suing a company for making misleading statements that distort its stock price. The outcome, which is likely to be decided by the politics of the individual justices, could Read More →
Read More →Amgen deals could foster biotech hub, panel says
Amgen’s decision to license some of its intellectual property to a new drug company that will operate near the biotechnical giant’s Thousand Oaks headquarters could be an exciting development for biotech firms in the 101 corridor, business leaders were told at a breakfast gathering Wednesday in Westlake Village. The move could be a start toward Read More →
Read More →Kleiner Perkins startup could spell new era for Amgen
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
